MX391180B - Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo - Google Patents

Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo

Info

Publication number
MX391180B
MX391180B MX2019005379A MX2019005379A MX391180B MX 391180 B MX391180 B MX 391180B MX 2019005379 A MX2019005379 A MX 2019005379A MX 2019005379 A MX2019005379 A MX 2019005379A MX 391180 B MX391180 B MX 391180B
Authority
MX
Mexico
Prior art keywords
preparation
pyrazolo
medical use
heteroaryl derivative
derivative
Prior art date
Application number
MX2019005379A
Other languages
English (en)
Other versions
MX2019005379A (es
Inventor
Chunfeng Shu
Feng He
Guobao Zhang
Qiyue Hu
Weikang Tao
Original Assignee
Jiangsu Hengrui Medicine Co
Shanghai hengrui pharmaceutical co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co, Shanghai hengrui pharmaceutical co ltd filed Critical Jiangsu Hengrui Medicine Co
Publication of MX2019005379A publication Critical patent/MX2019005379A/es
Publication of MX391180B publication Critical patent/MX391180B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen un derivado de pirazolo-heteroarilo, un método de preparación y su uso médico. En particular, la presente invención se refiere a un nuevo derivado de pirazolo-heteroarilo como el mostrado en la fórmula general (I), a un método de preparación del mismo y a una composición farmacéutica que contiene el derivado y a su uso como agente terapéutico, en particular como agonista de TLR7, en donde cada sustituyente en la fórmula general (I) se define en la descripción.
MX2019005379A 2016-11-28 2017-11-27 Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo MX391180B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201611066071 2016-11-28
PCT/CN2017/113007 WO2018095426A1 (zh) 2016-11-28 2017-11-27 吡唑并杂芳基类衍生物、其制备方法及其在医药上的应用

Publications (2)

Publication Number Publication Date
MX2019005379A MX2019005379A (es) 2019-09-04
MX391180B true MX391180B (es) 2025-03-21

Family

ID=62194797

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019005379A MX391180B (es) 2016-11-28 2017-11-27 Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo

Country Status (16)

Country Link
US (2) US11117898B2 (es)
EP (1) EP3546457B1 (es)
JP (1) JP7145854B2 (es)
KR (1) KR20190084991A (es)
CN (1) CN108884092B (es)
AU (1) AU2017366621B2 (es)
BR (1) BR112019010182A2 (es)
CA (1) CA3044903A1 (es)
ES (1) ES2886973T3 (es)
HU (1) HUE054964T2 (es)
MX (1) MX391180B (es)
MY (1) MY192084A (es)
PT (1) PT3546457T (es)
RU (1) RU2748833C2 (es)
TW (1) TWI760390B (es)
WO (1) WO2018095426A1 (es)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA46535A (fr) 2016-10-14 2019-08-21 Prec Biosciences Inc Méganucléases modifiées spécifiques de séquences de reconnaissance dans le génome du virus de l'hépatite b
CN111511754B (zh) 2017-12-20 2023-09-12 捷克共和国有机化学与生物化学研究所 活化sting转接蛋白的具有膦酸酯键的2’3’环状二核苷酸
EP3728283B1 (en) 2017-12-20 2023-11-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
KR102526964B1 (ko) 2018-02-26 2023-04-28 길리애드 사이언시즈, 인코포레이티드 Hbv 복제 억제제로서의 치환된 피롤리진 화합물
WO2019195181A1 (en) 2018-04-05 2019-10-10 Gilead Sciences, Inc. Antibodies and fragments thereof that bind hepatitis b virus protein x
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TW201945388A (zh) 2018-04-12 2019-12-01 美商精密生物科學公司 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶
WO2019209811A1 (en) 2018-04-24 2019-10-31 Bristol-Myers Squibb Company Macrocyclic toll-like receptor 7 (tlr7) agonists
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
JP2021526520A (ja) * 2018-05-25 2021-10-07 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Ｊｉａｎｇｓｕ Ｈｅｎｇｒｕｉ Ｍｅｄｉｃｉｎｅ Ｃｏ．， Ｌｔｄ． ピラゾロヘテロアリール誘導体の塩酸塩の結晶形および調製方法
CN110526918B (zh) * 2018-05-25 2021-09-03 江苏恒瑞医药股份有限公司 一种吡唑并杂芳基类衍生物的晶型及制备方法
CN110526917B (zh) * 2018-05-25 2021-09-03 江苏恒瑞医药股份有限公司 一种吡唑并杂芳基类衍生物的可药用盐、晶型及其制备方法
WO2020028097A1 (en) 2018-08-01 2020-02-06 Gilead Sciences, Inc. Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid
US11554120B2 (en) 2018-08-03 2023-01-17 Bristol-Myers Squibb Company 1H-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (TLR7) agonists and methods and uses therefor
WO2020063858A1 (zh) * 2018-09-29 2020-04-02 江苏恒瑞医药股份有限公司 Tlr激动剂与免疫检查点抑制剂联合在制备治疗肿瘤的药物中的用途
WO2020073942A1 (zh) * 2018-10-11 2020-04-16 江苏恒瑞医药股份有限公司 一种tlr7激动剂前药、其制备方法及其在医药上的应用
FI3873903T3 (fi) 2018-10-31 2024-03-26 Gilead Sciences Inc Substituoituja 6-azabentsiimidatsoliyhdisteitä HPK1-inhibiittoreina
KR102658602B1 (ko) 2018-10-31 2024-04-19 길리애드 사이언시즈, 인코포레이티드 Hpk1 억제 활성을 갖는 치환된 6-아자벤즈이미다졸 화합물
IL285315B2 (en) * 2019-02-07 2025-12-01 Beigene Ltd Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as tlr7 agonist
WO2020162705A1 (ko) 2019-02-08 2020-08-13 성균관대학교산학협력단 톨-유사 수용체 7 또는 8 작용자와 콜레스테롤의 결합체 및 그 용도
CA3129011C (en) 2019-03-07 2023-12-19 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 3'3'-cyclic dinucleotides and prodrugs thereof
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
EP3934757B1 (en) 2019-03-07 2023-02-22 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 2'3'-cyclic dinucleotides and prodrugs thereof
TW202210480A (zh) 2019-04-17 2022-03-16 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI751517B (zh) 2019-04-17 2022-01-01 美商基利科學股份有限公司 類鐸受體調節劑之固體形式
TWI826690B (zh) 2019-05-23 2023-12-21 美商基利科學股份有限公司 經取代之烯吲哚酮化物及其用途
CN112007034B (zh) * 2019-05-31 2022-05-24 江苏恒瑞医药股份有限公司 Tlr激动剂与免疫检查点抑制剂、vegfr抑制剂联合在制备治疗肿瘤药物中的用途
CN114040776B (zh) * 2019-06-28 2024-05-14 江苏恒瑞医药股份有限公司 Tlr激动剂与抗ox40抗体或其抗原结合片段联合在制备治疗肿瘤的药物中的用途
WO2021034804A1 (en) 2019-08-19 2021-02-25 Gilead Sciences, Inc. Pharmaceutical formulations of tenofovir alafenamide
KR20220074917A (ko) 2019-09-30 2022-06-03 길리애드 사이언시즈, 인코포레이티드 Hbv 백신 및 hbv를 치료하는 방법
CN112830929B (zh) * 2019-11-22 2022-09-16 江苏恒瑞医药股份有限公司 吡唑并杂芳基类化合物的制备方法
DK4069729T3 (da) 2019-12-06 2025-04-07 Prec Biosciences Inc Optimerede, modificerede meganukleaser med specificitet for en genkendelsessekvens i hepatitis b-virusgenomet
US20230127326A1 (en) 2020-01-27 2023-04-27 Bristol-Myers Squibb Company C3-SUBSTITUTED 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
EP4097102A1 (en) * 2020-01-27 2022-12-07 Bristol-Myers Squibb Company 1h-pyrazolo[4,3-d]pyrimidine compounds as toll-like receptor 7 (tlr7) agonists
KR20220132591A (ko) 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
KR20220132592A (ko) * 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
WO2021154668A1 (en) 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
WO2021154662A1 (en) 2020-01-27 2021-08-05 Bristol-Myers Squibb Company 1H-PYRAZOLO[4,3-d]PYRIMIDINE COMPOUNDS AS TOLL-LIKE RECEPTOR 7 (TLR7) AGONISTS
CN115151548A (zh) * 2020-01-27 2022-10-04 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
KR20220132594A (ko) 2020-01-27 2022-09-30 브리스톨-마이어스 스큅 컴퍼니 톨-유사 수용체 7 (TLR7) 효능제로서의 1H-피라졸로[4,3-d]피리미딘 화합물
CN115279765B (zh) * 2020-01-27 2024-11-12 百时美施贵宝公司 作为Toll样受体7(TLR7)激动剂的1H-吡唑并[4,3-d]嘧啶化合物
CA3170551A1 (en) 2020-03-02 2021-09-10 Yong Taik Lim Live-pathogen-mimetic nanoparticles based on pathogen cell wall skeleton, and production method thereof
AR121620A1 (es) 2020-03-20 2022-06-22 Gilead Sciences Inc Profármacos de nucleósidos 4’-c-sustituidos-2-halo-2’-deoxiadenosina y métodos de preparación y uso de los mismos
CN113801136B (zh) * 2020-06-16 2023-04-07 江苏恒瑞医药股份有限公司 咪唑并杂芳基类衍生物、其制备方法及其在医药上的应用
WO2022031011A1 (ko) 2020-08-04 2022-02-10 성균관대학교산학협력단 동력학적으로 작용하는 아주번트 앙상블
US20230346924A1 (en) 2020-08-04 2023-11-02 Progeneer Inc. Mrna vaccine comprising adjuvant capable of kinetic control
JP2023536954A (ja) 2020-08-04 2023-08-30 プロジェニア インコーポレイテッド 活性化部位が一時的に不活性化したトール様受容体７または８作用薬と機能性薬物の結合体およびその用途
CN114276351B (zh) * 2020-09-27 2023-06-16 江苏恒瑞医药股份有限公司 含氮杂环类衍生物、其制备方法及其在医药上的应用
CN114621230B (zh) * 2020-12-10 2023-06-16 江苏恒瑞医药股份有限公司 含氮杂环化合物、其制备方法及其在医药上的应用
EP4337223A1 (en) 2021-05-13 2024-03-20 Gilead Sciences, Inc. Combination of a tlr8 modulating compound and anti-hbv sirna therapeutics
AU2022299051B2 (en) 2021-06-23 2025-03-13 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240005901A (ko) 2021-06-23 2024-01-12 길리애드 사이언시즈, 인코포레이티드 디아실글리세롤 키나제 조절 화합물
AU2022298639C1 (en) 2021-06-23 2025-07-17 Gilead Sciences, Inc. Diacylglyercol kinase modulating compounds
KR20240025616A (ko) 2021-06-23 2024-02-27 길리애드 사이언시즈, 인코포레이티드 다이아실글리세롤 키나제 조절 화합물
CN118382625A (zh) * 2021-12-08 2024-07-23 上海维申医药有限公司 作为TLR7/8激动剂的吡啶[4,3-d]嘧啶类化合物
CN119604504A (zh) * 2022-09-16 2025-03-11 四川科伦博泰生物医药股份有限公司 一类双并环化合物、其制备方法及用途
CN119367281A (zh) * 2023-07-27 2025-01-28 苏州申拓医药科技有限公司 一种tlr7/8激动剂注射剂、其制备方法及其用途
CN119431359A (zh) * 2023-07-28 2025-02-14 苏州申拓医药科技有限公司 一种tlr7/8激动剂的可药用盐、晶型及其制备方法、药物组合物和用途
WO2025240244A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection
WO2025240242A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
WO2025240246A1 (en) 2024-05-13 2025-11-20 Gilead Sciences, Inc. Combination therapies with ribavirin
US20250345389A1 (en) 2024-05-13 2025-11-13 Gilead Sciences, Inc. Combination therapies

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1311499E (pt) 2000-08-08 2006-07-31 Ortho Mcneil Pharm Inc Compostos biciclicos como ligandos do receptor h3
ES2342069T4 (es) 2003-09-05 2011-01-26 Anadys Pharmaceuticals, Inc. Ligandos de tlr7 para el tratamiento de la hepatitis c.
EP1877407A1 (en) * 2005-04-25 2008-01-16 Novartis AG Imidazo(1,2-a)pyridine derivatives useful as peptide deformylase (pdf) inhibitors
JP2009528989A (ja) 2006-02-17 2009-08-13 ファイザー・リミテッド Ｔｌｒ７変調剤としての３−デアザプリン誘導体
BRPI0714831A2 (pt) 2006-07-18 2013-04-02 Anadys Pharmaceuticals Inc composto, composiÇço farmacÊutica e mÉtodos de modulaÇço de atividades imuno da citoquina em paciente, de tratamento de infecÇço de vÍrus c da hepatite em paciente e de desordem relacionada com proliferaÇço em mamÍfero necessitado do mesmo
JP5480637B2 (ja) * 2007-03-19 2014-04-23 アストラゼネカ・アクチエボラーグ Ｔｏｌｌ様受容体（ｔｌｒ７）モジュレーターとしての９−置換−８−オキソ−アデニン化合物
AR065784A1 (es) * 2007-03-20 2009-07-01 Dainippon Sumitomo Pharma Co Derivados de 8-oxo adenina,medicamentos que los contienen y usos como agentes terapeuticos para enfermedades alergicas, antivirales o antibacterianas.
WO2009034547A2 (en) * 2007-09-14 2009-03-19 Università Degli Studi Di Siena New 4-substituted derivatives of pyrazolo[3,4-d pyrimidine and pyrrolo[2,3-d]pyrimidine and uses thereof
AU2008323694A1 (en) * 2007-11-07 2009-05-14 Foldrx Pharmaceuticals, Inc. Modulation of protein trafficking
CA2711769A1 (en) 2008-01-17 2009-07-23 Dainippon Sumitomo Pharma Co. Ltd. Method for preparing adenine compound
WO2010077613A1 (en) * 2008-12-09 2010-07-08 Gilead Sciences, Inc. Modulators of toll-like receptors
GB0908772D0 (en) 2009-05-21 2009-07-01 Astrazeneca Ab New salts 756
EP2477987B1 (en) 2009-09-14 2018-01-10 Gilead Sciences, Inc. Modulators of toll-like receptors
CN102666541B (zh) * 2009-10-22 2015-11-25 吉里德科学公司 用于治疗特别是病毒感染的嘌呤或脱氮嘌呤的衍生物
JP5978226B2 (ja) 2010-12-17 2016-08-24 大日本住友製薬株式会社 プリン誘導体
KR101379808B1 (ko) * 2012-04-03 2014-04-24 울산대학교 산학협력단 산화질소 생성 억제용 피라졸로피리미딘 유도체 화합물
KR20160092991A (ko) * 2013-09-27 2016-08-05 님버스 아이리스 인코포레이티드 Irak 억제제 및 이의 용도
EP3116876A4 (en) * 2014-03-13 2017-10-25 Agency For Science, Technology And Research Fused pyrimidine-based hydroxamate derivatives
PL3134402T3 (pl) * 2014-04-22 2020-11-02 F.Hoffmann-La Roche Ag Związki 4-amino-imidazochinolinowe
LT3190113T (lt) * 2014-08-15 2021-08-25 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Pirolopirimidino junginiai, naudotini kaip tlr7 agonistai
CN105367576A (zh) * 2014-08-15 2016-03-02 正大天晴药业集团股份有限公司 作为tlr7激动剂的吡咯并嘧啶化合物
WO2016040419A1 (en) 2014-09-11 2016-03-17 Bristol-Myers Squibb Company Thioether triazolopyridine and triazolopyrmidine inhibitors of myeloperoxidase

Also Published As

Publication number Publication date
TWI760390B (zh) 2022-04-11
PT3546457T (pt) 2021-08-06
CA3044903A1 (en) 2018-05-31
CN108884092B (zh) 2021-06-29
BR112019010182A2 (pt) 2019-09-17
AU2017366621A1 (en) 2019-05-23
CN108884092A (zh) 2018-11-23
US11117898B2 (en) 2021-09-14
EP3546457A1 (en) 2019-10-02
EP3546457B1 (en) 2021-07-14
US20210380593A1 (en) 2021-12-09
JP7145854B2 (ja) 2022-10-03
ES2886973T3 (es) 2021-12-21
EP3546457A4 (en) 2020-05-20
KR20190084991A (ko) 2019-07-17
JP2019535730A (ja) 2019-12-12
US20210115046A1 (en) 2021-04-22
RU2019118390A3 (es) 2020-12-28
MY192084A (en) 2022-07-26
MX2019005379A (es) 2019-09-04
TW201819387A (zh) 2018-06-01
HUE054964T2 (hu) 2021-10-28
AU2017366621B2 (en) 2021-07-29
WO2018095426A1 (zh) 2018-05-31
RU2748833C2 (ru) 2021-05-31
RU2019118390A (ru) 2020-12-28

Similar Documents

Publication Publication Date Title
MX391180B (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo
PH12018502747A1 (en) Boronic acid derivatives and therapeutic uses thereof
MX2021007432A (es) Compuestos y composiciones para inhibir la actividad de shp2.
PH12017500281A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
MD4800B1 (ro) Compuşi de aminopirimidinil ca inhibitori de JAK
PH12017502001A1 (en) Amido-substituted cyclohexane derivatives
MX368504B (es) Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos.
GEP201706619B (en) New thienopyrimidine derivatives, a process for their preparation and pharmaceutical composition containing them
EA033266B1 (ru) Гидроксисложноэфирные производные, способ их получения и фармацевтические композиции, содержащие их
GEAP201914680A (en) New hydroxyacid derivatives, a process for their preparation and pharmaceutical compositions containing them
GEAP201914679A (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
MX2020013785A (es) Derivado de la pirido-pirimidina, metodo de preparacion del mismo y uso medico del mismo.
NZ711424A (en) Pyridine derivatives as soft rock inhibitors
PH12016500003A1 (en) Compounds and compositions as inhibitors of mek
MX2020011818A (es) Derivados de piridincarboxamida, su metodo de preparacion y sus usos farmaceuticos.
MY206745A (en) Pyridinyl sulfonamide derivatives, pharmaceutical compositions and uses thereof
MY181641A (en) Amino pyran ring derivative and composition and use thereof
TW201613578A (en) Pharmaceutical combinations
PH12016502352A1 (en) Pharmaceutical composition
PH12018500378A1 (en) Novel annelated phenoxyacetamides
PH12018502376A1 (en) Pyridinyl derivatives, pharmaceutical compositions and uses thereof as aoc3 inhibitors
TN2016000490A1 (en) Naphthyridinedione derivatives.
MX2017013099A (es) Metodos para el tratamiento de trastornos inflamatorios.
EA033423B1 (ru) Циклопропанбензофуранилпиридопиразиндионы
MX363622B (es) Nuevos derivados de amidinourea macrociclica, metodos de preparacion y usos de los mismos como inhibidores de quitinasa.